|
MechanismFGFR4 antagonists |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseSuspended |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Unknown statusPhase 1/2 A Phase I/II Study of FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors With Dose Escalation and Expansion to Selected Indications
The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of EVER4010001 in combination with Pembrolizumab in Patients with Advanced Solid Tumors. And in phase II to assess the anti-tumor efficacy of EVER4010001 in combination with Pembrolizumab in treating selected indications using appropriate biomarkers.
100 Clinical Results associated with EverNov Medicines (Zhuhai Hengqin) Co. Ltd.
0 Patents (Medical) associated with EverNov Medicines (Zhuhai Hengqin) Co. Ltd.
100 Deals associated with EverNov Medicines (Zhuhai Hengqin) Co. Ltd.
100 Translational Medicine associated with EverNov Medicines (Zhuhai Hengqin) Co. Ltd.